Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Phase 2
20 Years
74 Years
20 Years
74 Years
Not Enrolling
Female
Postmenopausal Women With Advanced Breast Cancer
Female
Postmenopausal Women With Advanced Breast Cancer
Trial Information
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Inclusion Criteria:
- Patients which participated in double blind study
Exclusion Criteria:
- Patients with intolerable toxicity.
- Patients which confirmed progressive disease during double blind study.
- Patients which have received concurrent anti-cancer therapy during double blind
study.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety during treatment
Principal Investigator
Novartis Pharmaceuticals
Investigator Role:
Study Director
Investigator Affiliation:
Novartis Pharmaceuticals
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
CFEM345 1601
NCT ID:
NCT00247663
Start Date:
December 1999
Completion Date:
Related Keywords:
- Postmenopausal Women With Advanced Breast Cancer
- Aromatase inhibitor
- letrozole
- breast cancer
- Breast Neoplasms
Name | Location |
|---|
